Details

Low-energy laser treatment study supported by National Eye Institute

image

NOVUS LIGHT TECHNOLOGIES TODAY - The National Eye Institute, part of the National Institutes of Health, recently awarded the University of Pittsburgh and West Virginia University $15.2 million to study how a treatment called selective laser trabeculoplasty (SLT) can be better used to treat glaucoma.

 “Our hope is that a brief low-energy laser procedure performed in the office once a year will effectively lower eye pressure without the hassle, expense, and side effects of daily medical therapy,” said the study’s principal investigator Tony Realini, professor of ophthalmology and glaucoma specialist at WVU.

“The eye drops only work if you put them in every day, in some cases several times a day,” said Goundappa K. Balasubramani, research associate professor in the Pitt Graduate School of Public Health’s Department of Epidemiology. “Dozens of studies have taught us that most patients do not faithfully adhere to their medication regimen daily as prescribed.”

Like eye drops, SLT also treats glaucoma by lowering eye pressure, but the procedure may only need to be performed once a year, allowing patients freedom from a daily treatment regimen. 

By identifying the best way to perform SLT to effectively manage glaucoma without eye drops, the researchers hope this study will change patients’ lives for the better. The study—a randomized clinical trial called “Clarifying the Optimal Application of SLT” or COAST—will compare standard SLT to low energy SLT and will also compare retreatment performed as needed when the effect wears off to retreatment annually to maintain eye pressure control without the need for medical therapy.

The researchers plan to enroll over 600 patients to receive treatment at up to 20 research centers. Patients will receive the laser treatment and their progress will be monitored over time. If the results of the trial are positive, the treatment plan for patients suffering from glaucoma could change for good.

“Our goal is to reduce the impact of this disease while improving patients’ quality of life,” said Stephen R. Wisniewski, professor of epidemiology and vice provost for budget and analytics at Pitt. 

Read full story



2/11/2021
print

Search for an Article